Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 4.02% is 72% below its 5-year average of 14.29%, near the low end of its 5-year range (4.02%–20.42%).
As of the fiscal period ended Tuesday, September 30, 2025. 52.09% below its 12-month average of 8.39%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-09-30.
RETURN ON EQUITY (ROE)
4.02%
RETURN ON EQUITY (ROE) AVG TTM
8.39%
RETURN ON EQUITY (ROE) AVG 3Y
11.64%
RETURN ON EQUITY (ROE) AVG 5Y
14.29%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.09%
CURRENT VS 3Y AVG
-65.45%
CURRENT VS 5Y AVG
-71.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+109.57%
vs the sector median at left
Jin Medical International Ltd.
Market Cap
$15.54M
Return on Equity (ROE)
4.02%
TTM Avg
8.39%
3Y Avg
11.64%
5Y Avg
14.29%
Market Cap
$15.78M
Return on Equity (ROE)
-271.81%
TTM Avg
-934.34%
3Y Avg
-347.56%
5Y Avg
-265.02%
Market Cap
$15.79M
Return on Equity (ROE)
-348.81%
TTM Avg
-160.92%
3Y Avg
-184.71%
5Y Avg
-151.29%
Market Cap
$15.24M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$14.80M
Return on Equity (ROE)
N/A
TTM Avg
54.00%
3Y Avg
301.36%
5Y Avg
162.15%
Market Cap
$14.71M
Return on Equity (ROE)
-42.72%
TTM Avg
-65.53%
3Y Avg
-58.02%
5Y Avg
-43.63%
Market Cap
$16.43M
Return on Equity (ROE)
N/A
TTM Avg
-416.37%
3Y Avg
-259.03%
5Y Avg
-190.00%
Market Cap
$16.67M
Return on Equity (ROE)
-170.55%
TTM Avg
-79.16%
3Y Avg
-71.01%
5Y Avg
-42.13%
Market Cap
$16.58M
Return on Equity (ROE)
-101.76%
TTM Avg
-188.04%
3Y Avg
-167.76%
5Y Avg
-134.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jin Medical International Ltd. (ZJYL) | $15.54M | 4.02% | 8.39% | 11.64% | 14.29% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | -271.81% | -934.34% | -347.56% | -265.02% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.79M | -348.81% | -160.92% | -184.71% | -151.29% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.24M | -951.92% | -161.65% | -122.41% | -87.71% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.80M | N/A | 54.00% | 301.36% | 162.15% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.71M | -42.72% | -65.53% | -58.02% | -43.63% |
| Dyadic International, Inc. (DYAI)vs › | $16.43M | N/A | -416.37% | -259.03% | -190.00% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.67M | -170.55% | -79.16% | -71.01% | -42.13% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -101.76% | -188.04% | -167.76% | -134.95% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | -125.30% | 118.50% | 7030.24% | 4638.47% |
ROE
4.0%
ROA
2.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | 4.02% |
| 2024-09-30 | 12.76% |
| 2023-09-30 | 12.00% |
| 2022-09-30 | 17.76% |
| 2021-09-30 | 18.76% |
| 2020-09-30 | 20.42% |
| 2019-09-30 | 34.07% |
| 2018-09-30 | 40.90% |
